comparemela.com

Latest Breaking News On - Ultragenyx pharmaceutical inc - Page 2 : comparemela.com

Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)

Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Seven Eight Capital LP Purchases 26,831 Shares of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE)

Seven Eight Capital LP increased its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Free Report) by 140.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 45,906 shares of the biopharmaceutical company’s stock after purchasing an additional 26,831 shares during the […]

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) Shares Purchased by Seven Eight Capital LP

Seven Eight Capital LP increased its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Free Report) by 140.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 45,906 shares of the biopharmaceutical company’s stock after acquiring an additional 26,831 shares during the quarter. Seven […]

Ultragenyx to Participate at Goldman Sachs 45th Annual Global Healthcare Conference

NOVATO, Calif., June 04, 2024 (GLOBE NEWSWIRE) Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.